Paolo Falcucci
Overview
Explore the profile of Paolo Falcucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laquintana V, Mottini C, Marchesi F, Marcozzi B, Terrenato I, Sperandio E, et al.
Front Immunol
. 2024 Feb;
14:1221587.
PMID: 38343436
Background: Few data are available about the durability of the response, the induction of neutralizing antibodies, and the cellular response upon the third dose of the anti-severe acute respiratory syndrome...
2.
Marchesi F, Terrenato I, Papa E, Tomassi M, Falcucci P, Gumenyuk S, et al.
Ann Hematol
. 2024 Jan;
103(3):947-956.
PMID: 38189833
Data about biosimilar Peg-filgrastim (bioPEG) in autologous stem cell transplant (ASCT) are still scarce. The aim of this study has been to assess efficacy and safety of bioPEG among lymphoma...
3.
Autore F, Stirparo L, Innocenti I, Papa E, Marchesi F, Togni C, et al.
Front Oncol
. 2022 Dec;
12:897937.
PMID: 36531008
COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very...
4.
Marchesi F, Pimpinelli F, Giannarelli D, Ronchetti L, Papa E, Falcucci P, et al.
Leukemia
. 2021 Sep;
36(2):588-590.
PMID: 34545184
No abstract available.
5.
Marchesi F, Pimpinelli F, Sperandio E, Papa E, Falcucci P, Pontone M, et al.
Br J Haematol
. 2021 Sep;
196(2):362-367.
PMID: 34490627
No abstract available.
6.
Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al.
J Hematol Oncol
. 2021 Jul;
14(1):119.
PMID: 34325728
In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose...
7.
Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al.
J Hematol Oncol
. 2021 May;
14(1):81.
PMID: 34001183
Background: Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and 50 with myeloproliferative malignancies (MPM)...
8.
Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, et al.
N Engl J Med
. 2021 May;
384(19):1810-1823.
PMID: 33979489
Background: Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF V600E kinase-activating mutation plays a pathogenetic role. In clinical trials involving patients with refractory or relapsed...
9.
Autore F, Innocenti I, Corrente F, Del Principe M, Rosati S, Falcucci P, et al.
Front Oncol
. 2020 Jun;
10:848.
PMID: 32587827
Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl) associated with rituximab (R) in fludarabine-ineligible patients with treated and untreated chronic lymphocytic leukemia (CLL). We...
10.
Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, et al.
Cancers (Basel)
. 2019 Jun;
11(7).
PMID: 31248056
Chronic Lymphocytic Leukemia (CLL) patients with +12 have been reported to have specific clinical and biologic features. We performed an analysis of the association between demographic; clinical; laboratory; biologic features...